HOME >> BIOLOGY >> NEWS
Epilepsy drug poses high risk for fetal death and birth defects

St. Paul, Minn. -- The epilepsy drug valproate poses a higher risk for fetal death and birth defects than other commonly used epilepsy drugs, according to a study published in the August 8, 2006, issue of Neurology, the scientific journal of the American Academy of Neurology.

Of the four epilepsy drugs tested in the study, valproate posed the highest risk to the fetus with over 20 percent of the pregnancies exposed to valproate resulting in death or birth defects such as skull and limb deformities and brain, heart and lung problems.

The rate was lower for the drugs phenytoin, carbamazepine and lamotrigine. The study's findings are consistent with several other recent studies.

"The evidence is compelling that valproate poses a higher risk of birth defects than other commonly used epilepsy drugs," said study author Kimford Meador, MD, of the University of Florida in Gainesville, Florida and a fellow at the American Academy of Neurology. "Unfortunately, many doctors and pregnant women aren't aware of the risks."

The study examined 333 pairs of mother and child in the United States and the United Kingdom.

Meador is recommending doctors talk with their patients about the risks associated with valproate when choosing an epilepsy drug for women of child-bearing age. Patients already taking valproate should also be advised of the risk.

"Although valproate will continue to be an important treatment option in women who aren't able to use other epilepsy drugs, we're advising valproate not be used as the drug of first choice for women of child bearing potential, and when used, its dosage should be limited if possible," said Meador.


'"/>

Contact: Angela Babb
ababb@aan.com
651-695-2789
American Academy of Neurology
7-Aug-2006


Page: 1

Related biology news :

1. Epilepsy drug eases symptoms of inherited disorder that weakens muscles
2. Epilepsy by the numbers
3. Epilepsy Foundation announces free forum
4. Epilepsy and depression - A two-way street?
5. Cat hair at home poses an allergy risk, particularly for young children
6. Replacement warhead program poses challenges for weapons complex
7. Carnegie Mellon researcher proposes development of artificial cells to fight disease
8. Malaria poses additional risks for first-time mothers
9. One-two particle punch poses greater risk for astronauts
10. Mouse study reveals human X-SCID gene therapy poses substantial cancer risk
11. SNM opposes new payment caps on imaging services detailed in Federal Deficit Reduction Act

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/6/2020)... ... May 06, 2020 , ... ... http://www.brevitest.com ) will become the latest out-of-state company to partner with ... Harbor. , Brevitest has developed a point-of-care analyzer capable of accurately performing ...
(Date:5/1/2020)... ... 2020 , ... More than 600 people undergo genetic counseling and testing each ... led by two genetic counselors. , My Gene Counsel , a digital health ... UConn’s High Rick Program to ensure that UConn’s patients who have undergone genetic testing ...
(Date:4/28/2020)... (PRWEB) , ... April 27, 2020 , ... ... first-of-its-kind category-defining service was started by three teenagers with an idea to help ... the world during the time of great need and suffering, an outlet has ...
Breaking Biology News(10 mins):
(Date:5/30/2020)... ... 29, 2020 , ... Medrio, Inc., the leading provider of ... enabled Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics for conditions ... patient in (FPI) in just seven days. The Cytovale technology will allow patients ...
(Date:5/26/2020)... ... May 26, 2020 , ... Brilliant , the leading smart ... smart garage door openers, announce a new integration to bring more convenience, simplicity, and ... openers powered by Aladdin Connect® can now be controlled from Brilliant’s in-wall touchscreen control ...
(Date:5/21/2020)... ... May 20, 2020 , ... ... who will serve as the company’s executive vice president of product engineering and ... is disrupting the medical imaging space, bringing more than 24 years of technology ...
(Date:5/15/2020)... LEXINGTON, Mass. (PRWEB) , ... May 15, 2020 , ... ... announced the appointment of Richard Ganz as Executive Chairman. Mr. Ganz will continue ... nine years, as well as work closely with CEO Brian Miller and Sentien’s management ...
Breaking Biology Technology:
Cached News: